This phase II trial tests how well fezolinetant works in improving vasomotor symptoms (VMS) in breast cancer patients taking endocrine therapy (ET). Anti-hormone treatments are effective for lowering the risk of breast cancer but can cause bothersome VMS, such as hot flashes and night sweats. Fezolinetant inhibits the activity of the neurokinin type 3 receptor and has shown activity against VMS in postmenopausal women. Taking fezolinetant may work well at improving VMS in breast cancer patients taking ET.

Start Date31 Oct 2024

Sponsor / Collaborator

Rogel Cancer Center: University of Michigan

[+1]

NCT06440967 / RecruitingPhase 3

A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy

One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but cannot be given to women on hormone therapy for breast cancer. Fezolinetant, an alternative to HRT, treats hot flashes for women in menopause. As hot flashes happen in the same way for women on hormone therapy for breast cancer, fezolinetant could help these women. In this study, women on hormone therapy for breast cancer who have moderate to severe hot flashes will take part. They will either take fezolinetant or a placebo to treat their hot flashes. The placebo looks like fezolinetant but doesn't have any medicine in it.
The main aim of this study is to confirm if women who take fezolinetant have fewer hot flashes that are less severe compared to women who take the placebo.
Women 18 years or older seeking treatment for hot flashes. They can take part in the study if they have an average of 7 or more moderate to severe hot flashes each day. They are having hormone therapy for breast cancer from stage 0 (cancer cells that have not spread to nearby tissue) up to stage 3+ (the cancer has spread from the breast to the lymph nodes near the breast or the chest wall).
The women will be assigned 1 of 2 study treatments (fezolinetant or placebo) by chance alone. Treatment will be double-blinded. That means that the women in the study and the study doctors will not know who takes which of the study treatments (fezolinetant or placebo). Women who take part in the study will take 1 tablet every day for 52 weeks (1 year). Each woman will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. In the last 10 days before their next clinic visit, the women will record information about their hot flashes. They will also use another device to answer questions about how hot flashes affect their daily life. During the study, the women will visit their study clinic about every 4 weeks for a health check. This will include some blood and urine tests. The last clinic visit will be 3 weeks after the women take their last tablet of study treatment (fezolinetant or placebo).

Start Date31 Jul 2024

Sponsor / Collaborator

Astellas Pharma Global Development, Inc.

NCT06206421 / RecruitingPhase 3

A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed.
Researchers want to find other ways to treat hot flashes. Fezolinetant is a medicine to treat hot flashes in women going through menopause. Fezolinetant is an approved medicine in the US. Further studies are needed before it is available in other regions such as Asia.
In this study fezolinetant will be used to treat hot flashes in Japanese women going through menopause. This study will confirm the safety of fezolinetant and how well the women tolerate the treatment.
Women will either take fezolinetant or a placebo. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it.
The women will take 1 tablet of the study medicine (fezolinetant or the placebo) once a day for up to 52 weeks.
During the study, the women will visit their study clinic for a check-up about every 4 weeks for up to 52 weeks (1 year). At each visit they will be asked if they had any medical problems. Other checks will include a medical examination and vital signs (temperature, blood pressure and pulse). At some visits, the women will have an ECG to check their heart rhythm and some blood and urine samples will be taken for laboratory tests. During a couple of visits, women who have a womb (uterus) will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs.
The last clinic visit will be 3 weeks after the women take their final tablet of the study medicine (fezolinetant or the placebo).

Start Date22 Feb 2024

Sponsor / Collaborator

Astellas Pharma, Inc.

100 Clinical Results associated with Fezolinetant

100 Translational Medicine associated with Fezolinetant

100 Patents (Medical) associated with Fezolinetant

Literatures (Medical) associated with Fezolinetant

01 Jan 2025·European Journal of Obstetrics & Gynecology and Reproductive Biology

Comment on “Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to menopause: A systematic review and meta-analysis”

Letter

Author: de Oliveira, Helen Michaela ; Barbosa, Lucas M ; Barbosa, Osvaldo Gonçalves

01 Dec 2024·Archives of women's mental health

FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research

Article

Author: Rani, Payal ; Rani, Priya ; Mansoor, Malaika ; Zehra, Dua

Women going through menopause frequently experience vasomotor symptoms such as hot flashes, night sweats, and sleep disturbances, significantly influencing their quality of life. Hormonal therapy has been demonstrated to be beneficial in treating VMS. However, due to specific restrictions, it is not recommended for every woman. Fezolinetant, a neurokinin 3 antagonist and non-hormonal treatment for severe to moderate VMS, functions by inhibiting neuronal impulses originating from the hypothalamic thermoregulatory center. Current Skylight 2 and 4 trials statistically demonstrate the safety and acceptability of fezolinetant, with relatively few adverse effects reported. Fezolinetant has been shown great potential for treating menopausal-related VMS, supporting its further advancement. However, further investigation is required to thoroughly evaluate its safety, effectiveness, and its impact on sleep patterns.

01 Nov 2024·European Journal of Obstetrics & Gynecology and Reproductive Biology

Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape

Review

Author: Pertynska-Marczewska, Magdalena ; Pertynski, Tomasz

BACKGROUND:

Vasomotor symptoms (VMS) affect 70% of menopausal women and are considered as hallmark symptoms of the menopausal transition experienced by over three quarters of women and severely by 25% of women. Estrogen withdrawal alone is not fully responsible for the onset of the menopausal vasomotor symptoms and the mechanism of altered thermoregulation appears to be centrally mediated with alterations in hypothalamic neurotransmitters playing a key part. The loss of thermoregulatory control coexists with the altered Kisspeptin- Neurokinin B-Dynorphin-expressing (KNDy) neurons of the arcuate nucleus signaling triggered by menopause.

OBJECTIVE:

Aim of the review was to explore evidence-based non-hormonal pharmacological interventions for treating vasomotor symptoms.

METHODS:

Comprehensive overview of relevant literature.

CONCLUSIONS:

In the population where, hormonal options are contraindicated or not preferred by the patient, it is essential to explore evidence-based non-hormonal pharmacological interventions for treating vasomotor symptoms. The 2024 landscape of available treatments has expanded yet again, arming the providers with an even wider range of possibilities to help their patients. Fezolinetant, is the first NK3R antagonist developed for the purpose of treating hot flashes in menopausal women. NK3R antagonists provide a safe and effective treatment option for managing menopausal women with VMS.

News (Medical) associated with Fezolinetant

18 Dec 2024

·www.drugs.com

FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box Warning

WEDNESDAY, Dec. 18, 2024 -- The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah , a medication used to relieve hot flashes in menopausal women, due to rare but potentially severe liver risks. In new communication issued Dec. 17, the FDA advised that women taking Veozah should undergo regular blood testing to monitor liver health. Warning signs of liver injury can include fatigue, nausea, vomiting, dark urine, light-colored stool, or yellowing of the skin or eyes, a news release says. Patients experiencing these symptoms should immediately stop taking the medication and consult with their doctor. “It’s important to note that the overall benefit-risk of Veozah has not changed and remains positive, but we want to further ensure that patients and healthcare providers are aware of the potential side effects,” as well as recommended lab testing, Astellas Pharma, the manufacturer of the drug, said in a statement. Veozah was approved in 2023 . At the time, it was the first non-hormonal prescription option for treating hot flashes . The medication works by blocking neurokinin B, a receptor involved in the brain’s regulation of body temperature. Since its approval, the drug's popularity has grown steadily, with nearly 29,000 prescriptions filled in May 2024 alone, according to FDA data. The FDA’s heightened warning comes after reviewing a recent case where a patient developed elevated liver markers after taking Veozah for about 40 days. The patient’s symptoms resolved, and liver function normalized after stopping the medication. To minimize risk, the FDA recommends monthly blood tests for liver markers during the first three months of Veozah treatment and follow-up tests at months six and nine. Because medication effects can vary widely due to health, genetics, and other factors, the FDA emphasized that it is difficult to predict who might develop liver issues. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug Approval

16 Dec 2024

·www.drugs.com

FDA Adds Boxed Warning to Veozah (fezolinetant) to Highlight the Known Risk of Rare But Serious Liver Injury

Audience: Patient, Health Professional, OBGYN, Endocrinology AUDIENCE: Patient, Health Professional, OBGYN, Endocrinology ISSUE: The FDA is warning that Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, can cause rare but serious liver injury. If there are signs and symptoms suggesting liver injury, stopping the medicine could prevent worsening liver injury and potentially return liver function to normal. The FDA added a warning about the risk of liver injury to the existing warning about elevated liver function test values and required liver function testing in the prescribing information for Veozah. The FDA made this update after reviewing a post marketing report of a patient with elevated liver function test values and signs and symptoms of liver injury after taking the medicine for about 40 days. The FDA also added new recommendations for patients and health care professionals about increasing the frequency of liver function testing, adding monthly testing for the next 2 months after starting Veozah, and then at months 3, 6, and 9 of treatment as already recommended. The updated prescribing information also instructs patients to stop the medicine immediately and contact the health care professional who prescribed the medicine if signs and symptoms of liver injury occur. BACKGROUND: Veozah (fezolinetant) is a nonhormonal prescription medicine approved in May 2023 to reduce the frequency and severity of moderate to severe hot flashes caused by menopause. The medicine is in a drug class called neurokinin 3 (NK3) receptor antagonists. It works to restore the balance between estrogen hormones and a brain chemical called neurokinin B (NKB) by blocking the activities of the NK3 receptor, which plays a role in the brain’s control of body temperature. RECOMMENDATIONS: Patients and Caregivers Health Care Professionals Related Information [9/12/2024 - Drug Safety Communication - FDA] Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug Approval

10 Oct 2024

·www.prnewswire.com

Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause

TOKYO, Oct. 10, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, will be featured in four oral and two poster presentations during the International Menopause Society (IMS) 19th World Congress on Menopause in Melbourne, Australia, October 19-22. VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause.1,2 Marci English, Vice President, Head of BioPharma Development, Astellas "Astellas is committed to advancing innovative science, and the data at the World Congress on Menopause further our understanding of how VMS impacts individuals and women's preferences for treatment. In addition, we are excited to share trial design for our recently initiated HIGHLIGHT study assessing fezolinetant for the treatment of moderate to severe VMS in patients with breast cancer taking adjuvant endocrine therapy." Emad Siddiqui, M.D., Vice President, Head of Specialty Therapeutic Area for Medical Affairs, Astellas "We are dedicated to continuing to expand the knowledge about fezolinetant beyond the pivotal trials. Our presentations at the World Congress on Menopause encompass a broad range of clinical and health-related quality of life analyses that further highlight the safety and efficacy of fezolinetant, as well as its positive impact on patient-reported outcomes including sleep and productivity at work." Fezolinetant data will be featured in four oral and two poster presentations: Two oral presentations from the SKYLIGHT 1 and 2 studies focus on patient-reported sleep outcomes and impact on work productivity with fezolinetant (Menopause New Treatments 1 and 2; Monday, Oct. 21, 3:50-5:20 p.m.; A. Cano and R. Nappi, respectively). Two oral presentations from the DAYLIGHT study highlight response and quality of life in women treated with fezolinetant who are unsuitable for hormone therapy (Menopause New Treatments 1; Monday, Oct. 21, 3:50-5:20 p.m.; A. Hirschberg and M. Shapiro, respectively). Poster highlights analyses of clinical and nonclinical data demonstrating no association between fezolinetant treatment and incidence of malignant neoplasm (P073; Sunday, Oct. 20, 7:40-9 p.m.; M. Shapiro). Poster reviews study design for the recently initiated HIGHLIGHT 1 phase 3 clinical study designed to evaluate the efficacy and safety of fezolinetant for the treatment of moderate to severe VMS in women with stage 0 to 3 hormone receptor-positive breast cancer receiving adjuvant endocrine therapy (P055; Sunday, Oct. 20, 7:40-9 p.m.; P. Briggs). Two additional oral presentations highlight Australian women's preferences for treatment of VMS associated with menopause and results of a literature review designed to identify and characterize concepts relevant to individuals' experiences of VMS with a goal of informing the development of a culturally sensitive self-assessment tool for VMS. *VEOZA: Approved as "VEOZAH ™" in U.S. About the BRIGHT SKY™ Phase 3 Program The BRIGHT SKY pivotal trials, SKYLIGHT 1™ (NCT04003155) and SKYLIGHT 2™ (NCT04003142), enrolled over 1,000 menopausal women with moderate to severe VMS. The trials are double-blinded, placebo-controlled for the first 12 weeks followed by a 40-week treatment extension period. Women were enrolled at over 180 sites within the U.S., Canada and Europe. SKYLIGHT 4™ (NCT04003389) is a 52-week double-blinded, placebo-controlled study designed to investigate the long-term safety of fezolinetant. For SKYLIGHT 4, over 1,800 menopausal women with VMS were enrolled at over 180 sites within the U.S., Canada and Europe. About DAYLIGHT DAYLIGHT (NCT05033886) is a Phase 3b, randomized, double-blind, placebo-controlled, 24-week study to assess the efficacy and safety of fezolinetant in menopausal women aged 40-65 suffering from moderate to severe VMS and considered unsuitable for hormone therapy. A total of 453 women were enrolled at 69 sites in Canada, Europe and Turkey. About HIGHLIGHT 1™ HIGHLIGHT 1 (NCT06440967) is a randomized, placebo-controlled, double-blind, Phase 3 clinical study to assess the efficacy and safety of fezolinetant for the treatment of moderate to severe VMS in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy. Approximately 540 participants are planned to be randomized 1:1 to fezolinetant or placebo at up to 100 sites in Europe and Canada. The four coprimary endpoints are change in the frequency and severity of moderate to severe VMS from baseline to weeks 4 and 12. Patients will be treated for 52 weeks with a final evaluation at 55 weeks. About VEOZA™ (fezolinetant) VEOZA (fezolinetant) is a nonhormonal neurokinin 3 (NK3) receptor antagonist indicated in Australia for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause. VEOZA works by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin/dynorphin (KNDy) neuron to modulate neuronal activity in the brain's temperature control center (the hypothalamus) to reduce the number and intensity of hot flashes and night sweats.3,4,5 Important Safety Information The full Australian Product Information and Australian Public Assessment Report (AusPAR) for fezolinetant is available from the Australian Government Therapeutic Goods Administration. About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at . Cautionary Notes In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. References 1 Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005;3:47. 2 Jones RE, Lopez KH, eds. Human Reproductive Biology. 4th ed. Waltham, MA: Elsevier, 2014:120. 3 Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104:5893-5905. 4 Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27:382-392. 5 Fraser GL, Hoveyda HR, Clarke IJ, et al. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderate levels of ovarian hormones throughout the menstrual cycle. Endocrinology. 2015;156:4214-4225. SOURCE Astellas Pharma Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Phase 3Drug Approval

100 Deals associated with Fezolinetant

External Link

KEGG	Wiki	ATC	Drug Bank
D11976	Fezolinetant	-	DB15669

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hot Flashes	GB	Astellas Pharma, Inc.	18 Dec 2023
Vasomotor symptom	US	Astellas Pharma US, Inc.	12 May 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Menopausal syndrome	Phase 3	US	Astellas Pharma Global Development, Inc.	10 Jul 2019
Menopausal syndrome	Phase 3	CA	Astellas Pharma Global Development, Inc.	10 Jul 2019
Menopausal syndrome	Phase 3	CZ	Astellas Pharma Global Development, Inc.	10 Jul 2019
Menopausal syndrome	Phase 3	LV	Astellas Pharma Global Development, Inc.	10 Jul 2019
Menopausal syndrome	Phase 3	PL	Astellas Pharma Global Development, Inc.	10 Jul 2019
Menopausal syndrome	Phase 3	ES	Astellas Pharma Global Development, Inc.	10 Jul 2019
Menopausal syndrome	Phase 3	GB	Astellas Pharma Global Development, Inc.	10 Jul 2019
Liver Injury	Phase 1	US	Astellas Pharma Global Development, Inc.	02 Sep 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04451226 (MOONLIGHT 3, Pubmed)	Phase 3	Vasomotor symptom	150	Fezolinetant 30 mg	puowgxwceq(gxhzvfthyy) = ktxetgvpoy jabivatnum (hdiqszvhne ) View more	Positive	01 May 2024
NCT05033886 (DAYLIGHT, Corporate Publications) Manual	Phase 3	Vasomotor symptom	453	Fezolinetant	sapedizmln(lzgddcckxn) = fezolinetant 45 mg demonstrated a statistically significant reduction of -1.93 (p<0.001) compared to placebo ewptzmaibx (zxrualgmqu ) Met View more	Positive	30 Nov 2023
				Placebo
NCT04003142 \| NCT04003155 (FDA) Manual	Phase 3	Vasomotor symptom	1,022	VEOZAH 45 mg (Trial 1)	xumsvztxnr(jrxqxzwdgq) = yybptmjtxl saebrertfl (gyiqitiecn, 0.05) View more	Positive	12 May 2023
				Placebo (Trial 1)	xumsvztxnr(jrxqxzwdgq) = pvuilznlle saebrertfl (gyiqitiecn, 0.05) View more
NCT04003389 (SKYLIGHT 4, Pubmed)	Phase 3	Vasomotor symptom	1,831	Fezolinetant 30 mg	lszdwmftik(deokxcbqld) = aznbwcvyep nhzvxajejf (uktuyeizmm )	-	09 Mar 2023
				Fezolinetant 45 mg	acluevtpll(fkwqrlnstx) = drccnniqud tylfkuwxzx (hhqpsoyizq, 0 - 2.3)
NCT04003389 (SKYLIGHT 4, CTgov)	Phase 3	Hot Flashes \| Vasomotor symptom	1,831	placebo (Placebo)	rcirqvpvmv(bjrifzoffm) = gldpqwdmjd jlhjrssgmy (zuiztkvcpj, yneezmejwd - vqohgpxsmk) View more	-	01 Feb 2023
				fezolinetant (Fezolinetant 30 mg)	rcirqvpvmv(bjrifzoffm) = imcntwzzxo jlhjrssgmy (zuiztkvcpj, hgpdtahnhj - xpwspspihu) View more
NCT04451226 (MOONLIGHT 3, PRNewswire) Manual	Phase 3	Vasomotor symptom	150	Fezolinetant	blllbwjofx(vmrvymfbya) = generally consistent with previous Phase 3 studies of fezolinetant gzbtmheoea (qqxtlhlkej )	Positive	04 Sep 2022
NCT04003155 (Skylight 1, CTgov)	Phase 3	Hot Flashes \| Vasomotor symptom	527	placebo (Double-blind Period: Placebo)	bbtcejrfqv(qztttmyimg) = vlywpaghmk dgxggngwmy (elvxkbcxac, onnwooklxa - nqzduohcma) View more	-	12 Aug 2022
				fezolinetant (Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg)	xvnmdzqfrn(kbdunndjks) = liubqnvlsg ndvysdtawd (yzijqavhza, mdgmyzsvse - qugjrowwar) View more
NCT04003142 (Skylight 2, CTgov)	Phase 3	Menopausal syndrome \| Hot Flashes \| Vasomotor symptom	501	placebo (Double-blind Period: Placebo)	ncmcjhaltt(mymdojmomp) = jywykkqwcv rhzxwkmdxj (tmszsavrsf, vppsovebno - dkqgnvnzfc) View more	-	15 Jun 2022
				Fezolinetant (Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg)	kvxiepipyo(absulilqqs) = dxbxeylbqd euwzoogfqg (ttftzpyxpd, wqspuzaofl - nzzbrjeljs) View more
NCT03192176 (Pubmed \| Menopause) Manual	Phase 2	Vasomotor symptom	287	fezolinetant	wyoanmrxov(gvxslfzwhf) = -1.9 to -3.5/day gtxuebwtfv (vbmzeivsbp ) View more	Positive	01 Apr 2020
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis